Business
Sight Sciences, Pioneering the Development of the Standalone MIGS Market, Announces Publication of Favorable Two-Year Outcomes of Standalone Use of the OMNI® Surgical System in Mild to Moderate Open-Angle Glaucoma
Real-world data published in Clinical Ophthalmology show the safety, efficacy, and durability of effect of OMNI for use in a standalone procedure to reduce
About this update from Sight Sciences, Inc.
[{"type":"text","content":"Real-world data published in Clinical Ophthalmology show the safety, efficacy, and durability of effect of OMNI for use in a standalone procedure to reduce intraocular pressure and medication burden\nMENLO PARK, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying causes of the world's most prevalent eye diseases, today announced publication in Clinical Ophthalhmology of favorable 24-month outcomes from a single center open-label study of the OMNI® Surgical System conducted in Germany. OMNI is cleared by the U.S. Food and Drug Administration (FDA) and CE-Marked for canaloplasty followed by trabeculotomy to reduce intraocular pressure (IOP) in adult patients with primary open-angle glaucoma (POAG) (FDA) and open-angle glaucoma (CE).* Sight Sciences intends to further develop OMNI, and to seek regulatory clearance, for expanded indications. Results from the study, conducted and co-authored by Karsten Klabe, M.D. and Hakan Kaymak, M.D., report that use of OMNI to perform a standalone MIGS procedure (not combined with cataract surgery) in mild to moderate open-angle glaucoma resulted in statistically significant reductions in both IOP and IOP-lowering medication use at 24 months. The study included long-term (24-month) outcomes from 38 eyes of 27 subjects with open-angle glaucoma. First author, Dr. Klabe, directly performed canaloplasty followed by trabeculotomy on each patient using OMNI at his practice in Düsseldorf, Germany. Mean baseline IOP in the study decreased from 24.6 mmHg preoperatively to 14.7 and 14.9 mmHg at months 12 and 24, respectively, reductions of approximately 10 mmHg or approximately 40%. All subjects in the study, and 100% of eyes, had at least a 20% IOP reduction at 24 months. Mean baseline IOP-lowering medication also decreased from 1.9 average medications per patient to 0.5 medications at month 24. At 24 months, nearly 60% of eyes were free of IOP-lowering medication. Both IOP and IOP-lowering medication reduction outcomes in the study were statistically significant (p","length":3229,"tagName":"div"}]